| Name | Title | Contact Details |
|---|
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
Mixlab is a modern veterinary pharmacy that specializes in pharmaceutical manufacturing and compounding for veterinary use.
Invagen Pharmaceuticals Inc is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical equipment and supply company, incorporated in Dublin, Ireland, although its corporate offices are located in Mansfield, Massachusetts, USA. On June 29, 2007, Covidien became an independent publicly traded company after being spun off from Tyco International.